Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide

Intravenous Iron Therapy with Saccharated Iron Oxide

Saccharated Ferric Oxide-Induced Osteomalacia in Iron-Induced Osteopathy Due to Nephropathy

Adult-onset hypophosphatemic osteomalacia is very rare in well-developed countries [1]. The most likely diagnosis of such patients, if their diet contains enough vitamin D, is oncogenic or iatrogenic osteomalacia [2, 3]. Saccharated ferric oxide (SFO; [Fe(OH)3]m [C12H22O11]n) is an intravenous preparation indicated for patients with iron-deficiency anemia [4, 5]. Since its introduction into the...

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity

Ferric citrate hydrate was recently approved in Japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (CKD). The daily therapeutic dose is about 3 to 6 g, which comprises about 2 to 4 g of citrate. Oral citrate solubilizes aluminum that is present in food and drinking water, and opens the tight junctions in the intes...

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

BACKGROUND AND OBJECTIVES Ferric citrate hydrate is a novel iron-based phosphate binder being developed for hyperphosphatemia in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS A phase 3, multicenter, randomized, double blind, placebo-controlled study investigated the efficacy and safety of ferric citrate hydrate in nondialysis-dependent patients with CKD. Starting in April o...

Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate

Introduction In hemodialysis patients on ferric citrate hydrate, the increase in ferritin level is mainly due to the administration of the compound. We investigated possible other factors associated with ferritin level and how erythropoietin resistance index and erythropoiesis in those patients were affected. We looked at ferritin-elevating factors using data from a Japanese phase III long-term...